StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
October 27, 2017 4:18 PM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its European ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Jefferies Upgrades Merck (MRK) to Hold
October 31, 2017 3:51 AM
Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'
October 30, 2017 10:45 AM
Merck (MRK) PT Lowered to $64 at Bernstein
October 30, 2017 8:09 AM
Merck (MRK) PT Lowered to $69 at Leerink Partners
October 30, 2017 7:49 AM
SunTrust Robinson Humphrey Downgrades Merck (MRK) to Hold
October 30, 2017 5:26 AM
Morgan Stanley Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:11 AM
Barclays Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:05 AM
Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
October 27, 2017 4:17 PM
